fluorouracil and Cardiac Diseases studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

Excerpt	Relevance	Reference
"Trastuzumab in combination with capecitabine is highly active in women with HER2-overexpressing metastatic breast cancer and is well tolerated."	9.13	A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. ( Iwase, S; Kitamura, K; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D, 2008)
"Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy."	9.12	Lapatinib plus capecitabine for HER2-positive advanced breast cancer. ( Berger, M; Cameron, D; Campone, M; Chan, A; Chan, S; Crown, J; Davidson, N; Forster, J; Geyer, CE; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Oliva, C; Pienkowski, T; Romieu, CG; Rubin, SD; Skarlos, D; Stein, S, 2006)
"Between 1986 and 1990, 621 patients with operable breast cancer were randomly assigned to receive fluorouracil (Roche SA, Basel, Switzerland) 500 mg/m2, epirubicin (Pharmacia SA, Milan, Italy) 50 mg/m2, and cyclophosphamide (Asta Medica AG, Frankfurt, Germany) 500 mg/m2 every 21 days (FEC 50) for six cycles (6 FEC 50); FEC 50 for three cycles (3 FEC 50); or the same regimen with epirubicin 75 mg/m2 (FEC 75) for three cycles (3 FEC 75)."	9.10	Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. ( Brémond, A; Clavère, P; Datchary, J; Facchini, T; Fargeot, P; Fumoleau, P; Goudier, MJ; Jacquin, JP; Kerbrat, P; Luporsi, E; Mihura, J; Monnier, A; Namer, M; Pourny, C; Ramos, R; Romestaing, P; Schraub, S; Seffert, P; Serin, D; Sztermer, JF, 2003)
"Between April 1990 and July 1993, 565 operable breast cancer patients with either more than three positive nodes or between one and three positive nodes with Scarff Bloom Richardson grade > or = 2 and hormone receptor negativity were randomized after surgery to receive either fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), and cyclophosphamide 500 mg/m(2) every 21 days for six cycles (FEC 50) or the same regimen except with epirubicin dose of 100 mg/m(2) (FEC 100)."	9.09	Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. ( , 2001)
"Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based."	8.89	Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. ( Cool, M; Deboever, G; Hiltrop, N; Lambrecht, G, 2013)
"5-fluorouracil (5-FU) is a widely used chemotherapeutic agent but cardiotoxicity challenges its clinical usefulness."	8.12	Cardioprotective effects of bosentan in 5-fluorouracil-induced cardiotoxicity. ( Abdel-Gaber, SA; Hafez, SMNA; Khalaf, HM; Rahman, SAAE; Refaie, MMM, 2022)
"Severe 5-fluorouracil-induced cardiotoxicity is rare, but can be severe and may mimic acute myocardial infarction, leading to diagnostic and therapeutic dilemmas."	7.71	5-fluorouracil-induced cardiotoxicity mimicking myocardial infarction: a case report. ( Campbell, NP; McGlinchey, PG; Webb, ST, 2001)
" We treated 40 evaluable patients with metastatic breast cancer and no prior exposure to chemotherapy with 5-fluorouracil, pirarubicin, and cyclophosphamide at 21-day intervals until reaching cumulative doses of 800 mg/m2 of pirarubicin, or the development of progressive disease."	7.68	Pirarubicin in combination chemotherapy for metastatic breast cancer. ( Buzdar, AU; Fraschini, G; Frye, D; Hortobagyi, GN; Ro, JS; Salewski, E; Tashima, CK; Theriault, RL; Walters, RS, 1990)
"In intermediate-risk breast cancer, complete hormonal blockade and chemotherapy provided similar outcomes."	6.72	Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. ( Bonneterre, J; Chollet, P; Clavère, P; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Monnier, A; Roché, H; Serin, D, 2006)
"Trastuzumab in combination with capecitabine is highly active in women with HER2-overexpressing metastatic breast cancer and is well tolerated."	5.13	A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. ( Iwase, S; Kitamura, K; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D, 2008)
"Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy."	5.12	Lapatinib plus capecitabine for HER2-positive advanced breast cancer. ( Berger, M; Cameron, D; Campone, M; Chan, A; Chan, S; Crown, J; Davidson, N; Forster, J; Geyer, CE; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Oliva, C; Pienkowski, T; Romieu, CG; Rubin, SD; Skarlos, D; Stein, S, 2006)
"Between 1986 and 1990, 621 patients with operable breast cancer were randomly assigned to receive fluorouracil (Roche SA, Basel, Switzerland) 500 mg/m2, epirubicin (Pharmacia SA, Milan, Italy) 50 mg/m2, and cyclophosphamide (Asta Medica AG, Frankfurt, Germany) 500 mg/m2 every 21 days (FEC 50) for six cycles (6 FEC 50); FEC 50 for three cycles (3 FEC 50); or the same regimen with epirubicin 75 mg/m2 (FEC 75) for three cycles (3 FEC 75)."	5.10	Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. ( Brémond, A; Clavère, P; Datchary, J; Facchini, T; Fargeot, P; Fumoleau, P; Goudier, MJ; Jacquin, JP; Kerbrat, P; Luporsi, E; Mihura, J; Monnier, A; Namer, M; Pourny, C; Ramos, R; Romestaing, P; Schraub, S; Seffert, P; Serin, D; Sztermer, JF, 2003)
"Between April 1990 and July 1993, 565 operable breast cancer patients with either more than three positive nodes or between one and three positive nodes with Scarff Bloom Richardson grade > or = 2 and hormone receptor negativity were randomized after surgery to receive either fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), and cyclophosphamide 500 mg/m(2) every 21 days for six cycles (FEC 50) or the same regimen except with epirubicin dose of 100 mg/m(2) (FEC 100)."	5.09	Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. ( , 2001)
" We performed a pharmacoeconomic evaluation of the ability of dexrazoxane to prevent cardiac-related adverse events in patients with Stage IIIB or IV metastatic breast cancer who were treated with a median of 10 cycles of intravenous FAC (5-fluorouracil, doxorubicin and cyclophosphamide) at doses of 500/50/500 mg/m2 respectively."	5.08	Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation. ( Arundell, E; Bates, M; Lieu, D; Tonkin, K; Williamson, T; Zagari, M, 1996)
" administration of different doses of ADR-529 (600-1000 mg/m2) together with different doses of epirubicin (E, 60-100 mg/m2), fixed-dose cyclophosphamide (C, 600 mg/m2), fixed-dose 5-fluorouracil (F, 600 mg/m2), and daily administration of tamoxifen (T, 30 mg; CEF-T) in the treatment of patients with metastatic breast cancer."	5.07	The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients. ( Bastholt, L; Gjedde, SB; Jakobsen, P; Mirza, MR; Mouridsen, HT; Rose, C; Sørensen, B, 1994)
" In this article, the current knowledge on the prevention, monitoring and treatment of cardiotoxicity induced by medical anti-cancer treatment with focus on anthracyclines, trastuzumab and 5-fluorouracil is described."	4.98	[Management of cardiovascular complications secondary to medical treatment of cancer]. ( Banke, A; Fosbøl, EL; Nielsen, D; Nielsen, KM; Overgaard, U; Polk, A; Schou, M; Vaage-Nielsen, M; Videbæk, L, 2018)
"Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based."	4.89	Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. ( Cool, M; Deboever, G; Hiltrop, N; Lambrecht, G, 2013)
"The standard preoperative treatment for resectable locally advanced esophageal squamous cell carcinoma (LAESCC) in Japan is docetaxel, cisplatin (CDDP), and 5-fluorouracil."	4.31	Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin. ( Daiko, H; Hashimoto, T; Hirose, T; Honma, Y; Ikeda, G; Ishiyama, K; Itoyama, M; Kadono, T; Kato, K; Oguma, J; Ohara, A; Sekine, S; Yamamoto, S; Yokoyama, K, 2023)
"5-fluorouracil (5-FU) is a widely used chemotherapeutic agent but cardiotoxicity challenges its clinical usefulness."	4.12	Cardioprotective effects of bosentan in 5-fluorouracil-induced cardiotoxicity. ( Abdel-Gaber, SA; Hafez, SMNA; Khalaf, HM; Rahman, SAAE; Refaie, MMM, 2022)
"To evaluate the changes in left ventricular myocardial function in patients with colorectal cancer undergoing chemotherapy with mFOLFOX6 (oxaliplatin + 5-fluorouracil + calcium folinate) using three-dimensional speckle-tracking echocardiography (3D-STE)."	4.02	Use of spectral tracking technique to evaluate the changes in left ventricular function in patients undergoing chemotherapy for colorectal cancer. ( Dong, S; Feng, J; Guo, X; Huang, L; Liu, K; Lu, G; Qin, W; Wang, Z; Zhai, Z; Zhang, C, 2021)
" Possible risk factors are duration of treatment, capecitabine-based chemotherapy, pre-existing cardiac diseases and hypertension."	3.88	Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study. ( Chen, G; Dong, C; Li, W; Peng, J; Qiu, M; Wang, C; Wang, F; Wu, Q; Yu, H; Yuan, Y; Zhang, J; Zhang, M; Zhao, Q; Zhou, W; Zhu, B, 2018)
" We report the detailed assessment of few cardiac parameter of toxicity in patients of advanced colorectal carcinoma subjected to two Schedules of high and low dose Folinic Acid, 5-Fluorouracil, bolus and continuous infusion."	3.79	Comparative cardiac toxicity in two treatment schedules of 5-FU/LV for colorectal carcinoma. ( Bano, N; Mateen, A; Najam, R, 2013)
"We reported a case of large right atrial thrombus which migrated from the inferior vena cava after acute left ventricular dysfunction due to 5-Fluorouracil cardiotoxicity."	3.74	Right atrial thrombus from inferior vena cava after acute cardiotoxicity of 5-fluorouracil. ( Goudev, A; Kinova, E; Zlatareva, N, 2008)
"Severe 5-fluorouracil-induced cardiotoxicity is rare, but can be severe and may mimic acute myocardial infarction, leading to diagnostic and therapeutic dilemmas."	3.71	5-fluorouracil-induced cardiotoxicity mimicking myocardial infarction: a case report. ( Campbell, NP; McGlinchey, PG; Webb, ST, 2001)
"Between 1975 and 1986, 326 patients with stage II breast cancer were treated with an adjuvant combination of doxorubicin, vincristine, cyclophosphamide, and 5-fluorouracil (AVCF) following regional therapy (232 modified radical mastectomy, 94 lumpectomies, 304 irradiations)."	3.69	Adjuvant chemotherapy with doxorubicin-containing regimen for 326 stage II breast cancers: 15-year results. ( Achard, JL; Bélembaogo, E; Charrier, S; Chollet, P; Courtadon, M; Curé, H; Dauplat, J; de Latour, M; Ferrière, JP; Kwiatkowski, F, 1997)
" Nine patients had symptoms resembling myocardial ischemia, one patient died due to assumed myocardial infarction related closely to fluorouracil treatment, four patients had supraventricular arrhythmia, and one patient had congestive heart failure."	3.68	Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. ( Bokemeyer, C; Harstrick, A; Hiddemann, W; Köhne-Wömpner, CH; Mügge, A; Papageorgiou, E; Poliwoda, H; Schöber, C; Stahl, M; Wilke, H, 1993)
" We treated 40 evaluable patients with metastatic breast cancer and no prior exposure to chemotherapy with 5-fluorouracil, pirarubicin, and cyclophosphamide at 21-day intervals until reaching cumulative doses of 800 mg/m2 of pirarubicin, or the development of progressive disease."	3.68	Pirarubicin in combination chemotherapy for metastatic breast cancer. ( Buzdar, AU; Fraschini, G; Frye, D; Hortobagyi, GN; Ro, JS; Salewski, E; Tashima, CK; Theriault, RL; Walters, RS, 1990)
"In order to test the possible cardiac-sparing effect of doxorubicin administered by six-hour intravenous infusion and to prospectively evaluate the role of resting left ventricular ejection fraction in monitoring these patients, 33 women with advanced breast cancer were treated with combination chemotherapy containing 5-fluorouracil, cyclophosphamide, and doxorubicin."	3.67	Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. ( Blum, RH; Dubin, N; Green, MD; Muggia, FM; Roses, D; Sanger, J; Speyer, JL; Wernz, JC, 1985)
"H SC 600 mg confirmed to be a safe and tolerable option as adjuvant/neoadjuvant therapy in patients with HER2+ EBC and LABC."	2.87	Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. ( Bengala, C; Bisagni, G; Brandes, AA; Cagossi, K; Gianni, L; Gori, S; Iannacone, C; Montemurro, F; Morandi, P; Stell, A; Zamagni, C; Zambetti, M, 2018)
"In intermediate-risk breast cancer, complete hormonal blockade and chemotherapy provided similar outcomes."	2.72	Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. ( Bonneterre, J; Chollet, P; Clavère, P; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Monnier, A; Roché, H; Serin, D, 2006)
"Sixty-two patients with gastric cancer were evaluable, 30 in the 5-FU group and 32 in 4-epi-DX + 5-FU group."	2.66	Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer. ( Kolarić, K; Potrebica, V; Stanovnik, M, 1986)
"5-fluorouracil (5-FU) is a key chemotherapeutic agent in the treatment of many gastrointestinal tract adenocarcinomas."	2.48	5-fluorouracil induced cardiotoxicity: review of the literature. ( Foderaro, AE; Kim, J; Sorrentino, MF; Truesdell, AG, 2012)
"The most commonly treated tumors were gastrointestinal (60%), head and neck (22%) and breast (4%)."	2.45	Fluoropyrimidine-associated cardiotoxicity: revisited. ( Saif, MW; Shah, AR; Shah, MM, 2009)
" Knowledge of this toxicity can aid clinicians to choose the optimal and least toxic regimen suitable for an individual patient."	2.44	Cardiac toxicity: old and new issues in anti-cancer drugs. ( Barriuso, J; Belda, C; Brunello, A; Casado, E; Chiappori, A; de Castro, J; Feliu, J; González-Barón, M; Sereno, M, 2008)
" Experimental studies revealed potential mechanisms of cardiotoxicity ranging from direct toxic effects on vascular endothelium involving endothelial NO synthase leading to coronary spasms and endothelium independent vasoconstriction via protein kinase C."	2.43	Cardiotoxicity of 5-fluorouracil. ( Alter, P; Herzum, M; Maisch, B; Schaefer, JR; Soufi, M, 2006)
"5-fluorouracil (5FU) is a largely employed antimetabolite, responsible for several well-known toxicities like hand-foot syndrome, diarrhoea, mucositis or leucopenia."	2.42	[Cardiotoxicity of 5-fluorouracil]. ( Barry, S; Cohen, A; Debourdeau, P; Teixeira, L; Tournigand, C, 2004)
"Patients with malignancy may present with acute circulatory compromise requiring ICU monitoring and care."	2.41	Circulatory shock. ( Bogolioubov, A; Groeger, JS; Keefe, DL, 2001)
" The drug is well known for its adverse effects involving bone marrow, skin, mucous membranes, intestinal tract and central nervous system, whereas its cardiotoxicity is less familiar to clinicians."	2.40	Cardiotoxicity of the antiproliferative compound fluorouracil. ( Becker, K; Erckenbrecht, JF; Frieling, T; Häussinger, D, 1999)
"Paclitaxel also has been reported to cause arrhythmias and possibly ischemia."	2.39	Cardiotoxicity and cardioprotection during chemotherapy. ( Hochster, H; Speyer, J; Wasserheit, C, 1995)
" In order to evaluate their real incidence we looked for a relation between cardiac toxicity and clinical or 5 FU pharmacokinetic parameters."	2.38	[Acute cardiac toxicity of 5-fluorouracil: pharmacokinetic correlation]. ( Alain, P; Allain, YM; Dubin, J; Gamelin, E; Gamelin, L; Larra, F; Maillart, P; Minier, JF; Turcant, A, 1991)
" It has been shown experimentally that 5-FU has a direct toxic effect on the myocardium."	2.38	[Cardiotoxicity of 5-fluorouracil: coronary spasm? Apropos of 2 cases with normal coronarography]. ( Cristofini, P; Desnos, M; Funck, F; Guenot, O; Guerot, C; Hagege, A; Trotoux, J, 1989)
"5-Fluorouracil is a commonly administered chemotherapy agent that has infrequently been associated with cardiotoxicity."	2.38	5-Fluorouracil cardiotoxicity: a critical review. ( Gradishar, WJ; Vokes, EE, 1990)
"5-Fluorouracil (5FU) cardiotoxicity is thought to be an infrequent toxic effect, usually related to coronary vasospasm."	2.38	[Cardiotoxicity of continuous intravenous infusion of 5-fluorouracil: clinical study, prevention and physiopathology. Apropos of 13 cases]. ( Bachaud, JM; Bugat, R; Chevreau, C; de Forni, M; Delay, M; Sorbette, F, 1990)
"The toxic effects of 5-fluorouracil - an antimitotic drug widely used in the treatment of cancer - mainly affect the digestive tract and the blood."	2.37	[Cardiac toxicity of 5-fluorouracil. Review of the literature, 5 new cases]. ( Clavel, M; Grivet, B; Siméone, P, 1988)
"Cardiotoxicity is a severe side effect for colorectal cancer (CRC) patients undergoing fluoropyrimidine-based chemotherapy."	1.72	Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy. ( Chen, L; Chou, C; Li, C; Ngorsuraches, S; Qian, J, 2022)
" All studies collected cardiovascular AEs using the Common Terminology Criteria for Adverse Events version available at the time of the study."	1.51	Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal. ( Brell, JM; Carver, JR; Denlinger, CS; Dimond, EP; Kircher, SM; Ky, B; O'Neill, A; Upshaw, JN; Wagner, LI, 2019)
" These results suggest that while FP chemotherapy-induced nausea, vomiting, and renal damage are serious adverse effects, further attention should also be paid to the potential cardiotoxic effects of FP therapy."	1.40	[Risk factors for cardiotoxicity during fluorouracil and cisplatin combination chemotherapy]. ( Kaise, M; Maruyama, Y; Nagai, H; Okura, Y; Sasaki, S; Yoshino, M, 2014)
" Raltitrexed, alone or in combination with oxaliplatin or irinotecan, provides a safe option in terms of cardiac toxicity for such patients."	1.40	Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. ( Ferry, D; Fournier, M; Gebski, V; Gordon, S; Karapetis, CS; Price, TJ; Ransom, D; Simes, RJ; Tebbutt, N; Wilson, K; Yip, D, 2014)
"Identifying breast cancer patients at high risk of developing cardiotoxicity after anthracycline therapy would be of value in guiding the use of these agents."	1.39	Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma. ( Feola, M; Garrone, O; Lo Nigro, C; Merlano, M; Monteverde, M; Vivenza, D, 2013)
" Its adverse side effects involving bone marrow, skin, mucous membranes, GIT and CNS are well known, whereas its cardiotoxicity is relatively uncommon and occurs in 1."	1.38	5-Flourouracil cardiotoxicity - an elusive cardiopathy: case report. ( Bagdadi, F; Bhat, GM; Kasanna, B; Mir, MH; Qadri, S; Sarmast, AH; Showkat, HI, 2012)
"Patients diagnosed with stage III colon cancer in 1991 to 2005 were identified from the Surveillance, Epidemiology, and End Results-Medicare database."	1.38	Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer. ( Chan, W; Delclos, GP; Du, XL; Hu, CY, 2012)
" Cardiotoxicity causing angina, arrhythmia and infarction are serious adverse events associated with these agents."	1.36	[Cardiotoxicity induced by 5-fluorouracil or capecitabine]. ( Baeksgaard, L; Jensen, SA; Petersen, LN; Reiter, L; Sørensen, JB, 2010)
"Sequential and combined doxorubicin/docetaxel/CMF regimens plus conventional RT in selected non high-risk cardiac patients are relatively safe without cardiac toxicity at mid-term follow-up."	1.35	Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients. ( Castadot, P; Chargari, C; Di Leo, A; Magné, N; Philippson, C; Van Houtte, P, 2009)
"The present study supports the toxic effect of 5-FU on the myocardium, which is largely schedule-dependent, whereas a low but finite risk of such toxicity has been observed with oral capecitabine."	1.35	Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. ( Kallistratos, MS; Karabelis, A; Kopterides, P; Kosmas, C; Mylonakis, N; Skopelitis, H; Syrios, J; Tsavaris, N, 2008)
" Coronary spasm is the most commonly suspected hypothesis, but further studies are warranted to seek for toxic inflammatory lesions of the myocardium (apoptosis, necrosis, fibrosis)."	1.33	Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. ( Barel, C; Belkhiria, M; Bui-Xuan, B; Descotes, J; Lombard-Bohas, C; Tabib, A; Timour, Q; Tsibiribi, P, 2006)
"Of 31,748 women with stage I to III breast cancer, 5,575 (18%) received chemotherapy."	1.33	Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. ( Doyle, JJ; Grann, VR; Hershman, DL; Jacobson, JS; Neugut, AI, 2005)
"Cardiotoxicity is an uncommon side-effect of 5-FU-based chemotherapy."	1.30	Endothelin-1 and 5-fluorouracil-induced cardiotoxicity. ( Ferrari, S; Moroni, M; Nastasi, G; Porta, C, 1998)
"Cardiotoxicity is a serious but relatively unknown side-effect of treatment with 5-fluorouracil (5-FU)."	1.29	Changes of blood viscosity in patients treated with 5-fluorouracil--a link to cardiotoxicity? ( Albertsson, M; Cwikiel, M; Eskilsson, J; Larsson, H; Persson, SU, 1995)
"5-Fluorouracil is widely known to be toxic to the hematopoietic and gastrointestinal systems."	1.29	Clinical cardiotoxicity of 5-fluorouracil. ( Keefe, DL; Pierri, MK; Roistacher, N, 1993)
" The hypothesis of a toxic cardiomyopathic process requires further confirmation."	1.28	Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. ( Bachaud, JM; Canal, P; Carrié, D; Chevreau, C; de Forni, M; Jaillais, P; Lemaire, L; Malet-Martino, MC; Shubinski, RE; Soulié, P, 1992)
"Twenty-seven patients with squamous cell carcinoma of the head and neck were treated with bleomycin 7."	1.27	Bleomycin infusion followed by cyclophosphamide, methotrexate, and 5-fluorouracil in advanced squamous carcinoma of the head and neck. ( Biller, H; Brooks, S; Holland, JF; Ohnuma, T; Plasse, TF; Saponaro, E, 1984)
"Uracil plus tegafur was shown to be less toxic than the drug alone in all the species, and uracil was found to decrease the toxicity of tegafur."	1.27	Effect of coadministration of uracil on the toxicity of tegafur. ( Haruno, A; Kunimune, Y; Morita, K; Unemi, N; Yamamoto, J; Yamashita, K; Yoshimura, Y, 1984)
"Cardionecrosis is the irreversible consequence of cardiotoxicity."	1.27	Drug-induced cardionecrosis. ( Godfraind, T, 1984)
"5-fluorouracil is a drug that is widely used in cancerology."	1.27	[Cardiotoxicity of 5-fluorouracil. Characteristics, mechanism, practical management]. ( Alexandre, JB; Escudier, B; Guyot, JM; Leclercq, B; Morin, P; Nitenberg, G, 1986)
"Two percent had congestive heart failure associated with doxorubicin."	1.27	Early and delayed clinical cardiotoxicity of doxorubicin. ( Blumenschein, GR; Buzdar, AU; Marcus, C; Smith, TL, 1985)

Research

Studies (109)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Actual Dose of Trastuzumab Administered

Timeframe	Studies, this research(%)	All Research%
pre-1990	18 (16.51)	18.7374
1990's	32 (29.36)	18.2507
2000's	30 (27.52)	29.6817
2010's	24 (22.02)	24.3611
2020's	5 (4.59)	2.80

Authors	Studies
Meter, M	1
Gavran, I	1
Bajo, D	1
Duplancic, D	1
Li, C	1
Chen, L	1
Chou, C	1
Ngorsuraches, S	1
Qian, J	1
Refaie, MMM	1
Abdel-Gaber, SA	1
Rahman, SAAE	1
Hafez, SMNA	1
Khalaf, HM	1
Kadono, T	1
Yamamoto, S	1
Hirose, T	1
Ikeda, G	1
Ohara, A	1
Itoyama, M	1
Yokoyama, K	1
Honma, Y	1
Hashimoto, T	1
Sekine, S	1
Ishiyama, K	1
Oguma, J	1
Daiko, H	1
Kato, K	1
Kanduri, J	1
More, LA	1
Godishala, A	1
Asnani, A	1
Wang, Z	2
Qin, W	1
Zhai, Z	1
Huang, L	1
Feng, J	1
Guo, X	1
Liu, K	1
Zhang, C	1
Lu, G	1
Dong, S	1
Banke, A	1
Polk, A	2
Nielsen, D	1
Videbæk, L	1
Overgaard, U	1
Fosbøl, EL	1
Vaage-Nielsen, M	1
Nielsen, KM	1
Schou, M	1
Peng, J	1
Dong, C	1
Wang, C	1
Li, W	2
Yu, H	1
Zhang, M	1
Zhao, Q	1
Zhu, B	1
Zhang, J	1
Wang, F	1
Wu, Q	1
Zhou, W	1
Yuan, Y	1
Qiu, M	1
Chen, G	1
Upshaw, JN	1
O'Neill, A	1
Carver, JR	1
Dimond, EP	1
Denlinger, CS	1
Kircher, SM	1
Wagner, LI	1
Ky, B	1
Brell, JM	1
Zambetti, M	1
Montemurro, F	1
Morandi, P	1
Zamagni, C	1
Brandes, AA	1
Bisagni, G	1
Cagossi, K	1
Bengala, C	1
Gori, S	1
Iannacone, C	1
Stell, A	1
Gianni, L	1
Vaage-Nilsen, M	1
Vistisen, K	1
Nielsen, DL	1
Kelly, C	1
Bhuva, N	1
Harrison, M	1
Buckley, A	1
Saunders, M	1
Lotrionte, M	1
Cavarretta, E	1
Abbate, A	1
Mezzaroma, E	1
De Marco, E	1
Di Persio, S	1
Loperfido, F	1
Biondi-Zoccai, G	1
Frati, G	1
Palazzoni, G	1
Vivenza, D	1
Feola, M	1
Garrone, O	1
Monteverde, M	1
Merlano, M	1
Lo Nigro, C	1
Najam, R	1
Bano, N	1
Mateen, A	1
Gurzu, S	1
Jung, I	1
Comsulea, M	1
Kadar, Z	1
Azamfirei, L	1
Molnar, C	1
Ransom, D	1
Wilson, K	1
Fournier, M	1
Simes, RJ	1
Gebski, V	1
Yip, D	1
Tebbutt, N	1
Karapetis, CS	1
Ferry, D	1
Gordon, S	1
Price, TJ	1
Lamberti, M	1
Porto, S	1
Zappavigna, S	1
Addeo, E	1
Marra, M	1
Miraglia, N	1
Sannolo, N	1
Vanacore, D	1
Stiuso, P	1
Caraglia, M	1
Kaise, M	1
Yoshino, M	1
Nagai, H	1
Sasaki, S	1
Okura, Y	1
Maruyama, Y	1
Schwameis, M	1
Thaler, J	1
Schober, A	1
Schörgenhofer, C	1
Kulinna-Cosentini, C	1
Laggner, A	1
Röggla, M	1
Jilma, B	1
Piuhola, J	1
Tenhunen, O	1
Kerkelä, R	1
Kinova, E	1
Zlatareva, N	1
Goudev, A	1
Magné, N	1
Castadot, P	1
Chargari, C	1
Di Leo, A	1
Philippson, C	1
Van Houtte, P	1
Saif, MW	3
Shah, MM	1
Shah, AR	1
Dalzell, JR	1
Samuel, LM	1
Willems, L	1
Suarez, F	1
Messas, E	1
Baubion, N	1
Decaudin, D	1
Fourquet, A	1
Ghez, D	1
Delarue, R	1
Hermine, O	1
Buzyn, A	1
Varet, B	1
Rubio, MT	1
Jensen, SA	2
Baeksgaard, L	1
Petersen, LN	1
Reiter, L	1
Sørensen, JB	2
Hu, CY	1
Chan, W	1
Delclos, GP	1
Du, XL	1
Almagro, BM	1
Steyls, MC	1
Navarro, NL	1
Domínguez, EG	1
Acosta, EH	1
Pérez, MA	1
Ceballos, EH	1
Khan, MA	1
Masood, N	1
Husain, N	1
Ahmad, B	1
Aziz, T	1
Naeem, A	1
Bhat, GM	1
Mir, MH	1
Showkat, HI	1
Kasanna, B	1
Bagdadi, F	1
Sarmast, AH	1
Qadri, S	1
Sorrentino, MF	1
Kim, J	1
Foderaro, AE	1
Truesdell, AG	1
Deboever, G	1
Hiltrop, N	1
Cool, M	1
Lambrecht, G	1
Fumoleau, P	2
Kerbrat, P	2
Romestaing, P	1
Fargeot, P	2
Brémond, A	1
Namer, M	1
Schraub, S	1
Goudier, MJ	2
Mihura, J	1
Monnier, A	2
Clavère, P	2
Serin, D	2
Seffert, P	1
Pourny, C	1
Facchini, T	1
Jacquin, JP	1
Sztermer, JF	1
Datchary, J	1
Ramos, R	1
Luporsi, E	1
Quinn, MG	1
Thomas, RR	1
Ernst, A	1
Grem, JL	1
TOURNEUR, R	1
GRIVAUX, M	1
LAMOTTE-BARRILLON, S	1
Bonneterre, JM	1
Teixeira, L	1
Barry, S	1
Debourdeau, P	1
Cohen, A	1
Tournigand, C	1
Rueckert, S	1
Ruehl, I	1
Kahlert, S	1
Konecny, G	1
Untch, M	1
Gul, M	1
Duzenli, A	1
Bircan, M	1
Cander, B	1
Kocak, S	1
Ozdemir, K	1
Doyle, JJ	1
Neugut, AI	1
Jacobson, JS	1
Grann, VR	1
Hershman, DL	1
Alter, P	1
Herzum, M	1
Soufi, M	1
Schaefer, JR	1
Maisch, B	1
Tsibiribi, P	1
Descotes, J	1
Lombard-Bohas, C	1
Barel, C	1
Bui-Xuan, B	1
Belkhiria, M	1
Tabib, A	1
Timour, Q	1
Roché, H	1
Bonneterre, J	1
Chollet, P	2
Guastalla, JP	1
Geyer, CE	1
Forster, J	1
Lindquist, D	1
Chan, S	1
Romieu, CG	1
Pienkowski, T	1
Jagiello-Gruszfeld, A	1
Crown, J	1
Chan, A	1
Kaufman, B	1
Skarlos, D	1
Campone, M	1
Davidson, N	1
Berger, M	1
Oliva, C	1
Rubin, SD	1
Stein, S	1
Cameron, D	1
Ozyiğit, T	1
Buğra, Z	1
Yamamoto, D	1
Iwase, S	1
Kitamura, K	1
Odagiri, H	1
Yamamoto, C	1
Nagumo, Y	1
Kosmas, C	1
Kallistratos, MS	1
Kopterides, P	1
Syrios, J	1
Skopelitis, H	1
Mylonakis, N	1
Karabelis, A	1
Tsavaris, N	1
Sereno, M	1
Brunello, A	1
Chiappori, A	1
Barriuso, J	1
Casado, E	1
Belda, C	1
de Castro, J	1
Feliu, J	1
González-Barón, M	1
Tomita, M	1
Ledbetter, L	1
Diasio, RB	1
Plasse, TF	1
Ohnuma, T	1
Brooks, S	1
Saponaro, E	1
Holland, JF	1
Biller, H	1
Tormey, DC	1
Weinberg, VE	1
Leone, LA	1
Glidewell, OJ	1
Perloff, M	1
Kennedy, BJ	1
Cortes, E	1
Silver, RT	1
Weiss, RB	1
Aisner, J	1
Yamamoto, J	1
Haruno, A	1
Yoshimura, Y	1
Unemi, N	1
Kunimune, Y	1
Yamashita, K	1
Morita, K	1
Pinelli, G	1
Lusa, AM	1
Salvarani, R	1
Di Pasquale, G	1
Roncuzzi, R	1
Coluccini, M	1
Godfraind, T	1
Vorobiof, DA	1
Hochster, H	1
Wasserheit, C	1
Speyer, J	1
Lemaire, L	2
Arellano, M	1
Malet-Martino, MC	2
Martino, R	1
De Forni, M	4
Armand, JP	1
Weidmann, B	2
Jansen, W	1
Heider, A	1
Niederle, N	2
Cwikiel, M	2
Persson, SU	1
Larsson, H	1
Albertsson, M	2
Eskilsson, J	1
Jakobsen, P	1
Sørensen, B	1
Bastholt, L	1
Mirza, MR	1
Gjedde, SB	1
Mouridsen, HT	1
Rose, C	1
Teipel, A	1
Birkenhake, S	1
Keefe, DL	2
Roistacher, N	1
Pierri, MK	1
Schöber, C	2
Papageorgiou, E	1
Harstrick, A	1
Bokemeyer, C	1
Mügge, A	1
Stahl, M	2
Wilke, H	2
Poliwoda, H	1
Hiddemann, W	1
Köhne-Wömpner, CH	1
Anderson, NR	1
Lokich, JJ	1
Moore, C	1
Robben, NC	1
Pippas, AW	1
Moore, JO	1
Lieutaud, T	1
Brain, E	1
Golgran-Toledano, D	1
Vincent, F	1
Cvitkovic, E	1
Leclercq, B	2
Escudier, B	2
Brestescher, C	1
Pautier, P	1
Farge, D	1
Ferrière, JP	1
Charrier, S	1
Curé, H	1
Kwiatkowski, F	1
Courtadon, M	1
Bélembaogo, E	1
de Latour, M	1
Achard, JL	1
Dauplat, J	1
Van Kuilenburg, AB	1
Vreken, P	1
Beex, LV	1
Meinsma, R	1
Van Lenthe, H	1
De Abreu, RA	1
van Gennip, AH	1
Porta, C	1
Moroni, M	1
Ferrari, S	1
Nastasi, G	1
Becker, K	1
Erckenbrecht, JF	1
Häussinger, D	1
Frieling, T	1
Kuropkat, C	1
Griem, K	1
Clark, J	1
Rodriguez, ER	1
Hutchinson, J	1
Taylor, SG	1
Cheriparambil, KM	1
Vasireddy, H	1
Kuruvilla, A	1
Gambarin, B	1
Makan, M	1
Saul, BI	1
López Medrano, F	1
Sánchez Muñoz, A	1
Sánchez Sánchez, V	1
Costa Pérez-Herrero, JR	1
Bogolioubov, A	1
Groeger, JS	1
Stockeld, D	1
Tennvall, J	1
Wagenius, G	1
Backman, L	1
Brodin, O	1
Granström, L	1
Gustafsson, G	1
Gustavsson, S	1
Hambraeus, G	1
Lewensohn, R	1
Sjöstedt, S	1
Strander, H	1
Aberg, B	1
Fagerberg, J	1
Winer, EP	1
Burstein, HJ	1
McGlinchey, PG	1
Webb, ST	1
Campbell, NP	1
Van Cutsem, E	1
Hoff, PM	1
Blum, JL	1
Abt, M	1
Osterwalder, B	1
Tonkin, K	1
Bates, M	1
Lieu, D	1
Arundell, E	1
Williamson, T	1
Zagari, M	1
Meinardi, MT	1
Van Der Graaf, WT	1
Gietema, JA	1
Van Den Berg, MP	1
Sleijfer, DT	1
De Vries, EG	1
Haaksma, J	1
Boomsma, F	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
National Phase IIIb Prospective Two-Cohort Non-Randomized, Multi-centre, Open Label Study to Assess the Safety of Subcutaneous Trastuzumab and Molecular Biomarkers in Patients With Early and Locally Advanced HER2-Positive Breast Cancer[NCT01940497]	Phase 3	240 participants (Actual)	Interventional	2013-11-15	Completed
Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients With Solid Tumors: A Retrospective, International and Non-interventional Study[NCT04260269]		200 participants (Anticipated)	Observational	2018-06-01	Enrolling by invitation
A Randomised, Multicentre, Open-label Phase II Trial Investigating Activity of Chemotherapy and Lapatinib and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer (MBC) Refractory to Anti HER2 Therapies[NCT02238509]	Phase 2	154 participants (Anticipated)	Interventional	2014-11-30	Recruiting
A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) Versus Capecitabine in Women With Refractory Advanced or Metastatic Breast Cancer[NCT00078572]	Phase 3	408 participants (Actual)	Interventional	2004-03-31	Completed
A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertu[NCT03272477]	Phase 2	257 participants (Actual)	Interventional	2017-10-05	Active, not recruiting
A Phase II Study of Lapatinib for the Treatment of Stage IV Melanoma Harboring ERBB4 Mutations[NCT01264081]	Phase 2	34 participants (Actual)	Interventional	2011-05-20	Terminated (stopped due to Protocol would not be able to reach stated accrual.)
Phase II Open-Label Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer[NCT01309607]	Phase 2	34 participants (Anticipated)	Interventional	2011-04-30	Active, not recruiting
Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases[NCT01934894]	Phase 2	11 participants (Actual)	Interventional	2014-05-31	Terminated (stopped due to Study was terminated due to lack of significant signal of efficacy)
Phase 1 Trial of Tucatinib, Trastuzumab, and Capecitabine With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From HER-2 Positive Breast Cancer[NCT05553522]	Phase 1	40 participants (Anticipated)	Interventional	2023-09-18	Recruiting
Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641]	Phase 2	100 participants (Anticipated)	Interventional	2019-01-28	Recruiting
Adjuvant Dose-dense Sequential Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study[NCT04829890]		89 participants (Actual)	Observational	2004-02-29	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Actual dose (mg) administered = (sum over all cycles of actual dose received [mg] divided by number of cycles). Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up last dose of trastuzumab (up to approximately 1 year)

Disease-Free Survival (DFS) Using Mammography

Intervention	mg (Mean)
Trastuzumab (Vial): Adjuvant	599.7
Trastuzumab (Vial): Neoadjuvant	600.00
Trastuzumab (SID): Adjuvant	593.3
Trastuzumab (SID): Neoadjuvant	595.9

DFS was defined as the time from the first treatment to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Kaplan-Meier estimates were used for analysis. Participants who were disease-free were censored at the data cut off date. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])

Duration of Treatment With Trastuzumab

Intervention	Months (Median)
Trastuzumab (Vial): Adjuvant	NA
Trastuzumab (Vial): Neoadjuvant	NA
Trastuzumab (SID): Adjuvant	NA
Trastuzumab (SID): Neoadjuvant	NA

Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up last dose of trastuzumab (up to approximately 1 year)

Overall Survival (OS)

Intervention	days (Mean)
Trastuzumab (Vial): Adjuvant	346
Trastuzumab (Vial): Neoadjuvant	352.2
Trastuzumab (SID): Adjuvant	340.1
Trastuzumab (SID): Neoadjuvant	351.9

Overall survival was defined as the time from the first treatment to death from any cause. Kaplan-Meier estimates were used for analysis. Participants who did not die were censored on the date they were last known to be alive. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to death due to any cause (up to approximately 4.5 years)

Percentage of Participants Who Died

Intervention	Months (Median)
Trastuzumab (Vial): Adjuvant	NA
Trastuzumab (Vial): Neoadjuvant	NA
Trastuzumab (SID): Adjuvant	NA
Trastuzumab (SID): Neoadjuvant	NA

Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to death due to any cause (up to approximately 4.5 years)

Percentage of Participants Who Received Concomitant Medications

Percentage of Participants With Event (Local, Regional or Distant Recurrence, Contralateral Breast Cancer or Death) Using Mammography

Intervention	Percentage of Participants (Number)
Trastuzumab (Vial): Adjuvant	5.2
Trastuzumab (Vial): Neoadjuvant	4.5
Trastuzumab (SID): Adjuvant	0.0
Trastuzumab (SID): Neoadjuvant	5.26

Intervention	Percentage of Participants (Number)
Trastuzumab (Vial)	100
Trastuzumab (SID)	100

A participant was considered as disease free if the participant was free from local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Percentage of participants with event at the cut off date were reported. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])

Percentage of Participants With Pathological Complete Response (pCR) (Neoadjuvant Groups Only) Using Mammography

Intervention	Percentage of Participants (Number)
Trastuzumab (Vial): Adjuvant	18.5
Trastuzumab (Vial): Neoadjuvant	33.3
Trastuzumab (SID): Adjuvant	6.6
Trastuzumab (SID): Neoadjuvant	11.1

In the neoadjuvant setting, the activity of two sequential drug regimens, doxorubicin-containing chemotherapy followed by paclitaxel or docetaxel chemotherapy in combination with trastuzumab, was assessed as the percentage of participants with pCR in breast and nodes using mammography. pCR was defined as the absence of histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast after preoperative treatment. Data for this outcome measure were analyzed and reported only for neoadjuvant groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to 24 weeks

Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

Intervention	Percentage of Participants (Number)
Trastuzumab (Vial): Neoadjuvant	40.9
Trastuzumab (SID): Neoadjuvant	15.8

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were the AEs occurring from starting on the day of or after first administration of trastuzumab and within 28 days after last dose of trastuzumab. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to 28 days after last dose of trastuzumab (up to approximately 1 year)

Percentage of Health Care Professionals (HCPs) by Response to Health Care Professional Questionnaire (HCPQ)

Intervention	Percentage of Participants (Number)
Trastuzumab (Vial): Adjuvant	98.9
Trastuzumab (Vial): Neoadjuvant	100.0
Trastuzumab (SID): Adjuvant	89.1
Trastuzumab (SID): Neoadjuvant	95.2

Percentage of HCPs providing responses to various questions related to overall ease of study drug administration was reported in different categories, where categories indicate all possible responses to such questions. (NCT01940497)
Timeframe: After at least 4 participants completed 5 cycles of adjuvant treatment (1 cycle = 21 days; maximum up to 1 year)

Percentage of Participants by Response to Patient Satisfaction Questionnaire (PSQ)

Intervention	Percentage of HCPs (Number)
	Specialization: Oncologist	Specialization: Specialist nurse	Specialization: Other	Specialization: Missing	Personally administered/supervised: Always	Personally administered/supervised: Sometimes	Personally administered/supervised: Never	If 'Never', who administered: Specialist nurse	Syringe prepared at: Pharmacy	Syringe prepared at: Oncology ward	Syringe prepared at: Missing	Time to fill syringe: less than (<) 5 minutes	Time to fill syringe: 6-10 minutes	Time to fill syringe: 11-15 minutes	Time to fill syringe: Unknown	Total time for vial administration: <3 minutes	Total time for vial administration: <5 minutes	Total time for vial administration: 6-15 minutes	Time to prepare SID: <5 minutes	Time to prepare SID: 6-10 minutes	Time to prepare SID: 11-15 minutes	Time to prepare SID: 16-20 minutes	Time to prepare SID: >20 minutes	Total time for SID administration: <3 minutes	Total time for SID administration: <5 minutes	Total time for SID administration: 6-15 minutes	Injection site: Irritation: A lot	Injection site: Irritation: A few	Injection site: Irritation: None	Injection site: Bruising: A few	Injection site: Bruising: None	Injection site: Infection: None	Fever,shivering,flu-like,rash,swelling:A few	Fever,shivering,flu-like,rash,swelling:None	Time at hospital for administration: <2 hours	Time at hospital for administration: >2, <3 hours	Time at hospital for administration: >3, <4 hours	Time at hospital for administration: >4 hours	Time at hospital for administration: Missing	Anxiety to participants: None	Anxiety to participants: A fair amount	Ease of vial administration: None	Ease of vial administration: A fair amount	Ease of vial administration: A lot	Subcutaneous route may simplify management: Yes	Subcutaneous route may simplify management: No	Would recommend SID to intravenous route: Yes	Would recommend SID to intravenous route: No	Would recommend subcutaneous route to medics: Yes	Would recommend subcutaneous route to medics: No	Would recommend subcutaneous to medics:Missing	Convenience of using SID by participants: Yes	Convenience of using SID by participants: No	Convenience of using SID by participants: Missing
HCPs: Trastuzumab (SID)	16.0	76.0	8.0	0.0	48.0	48.0	4.0	4.0	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	72.0	14.0	4.0	2.0	8.0	26.0	30.0	44.0	4.0	36.0	60.0	10.0	90.0	100.0	14.0	86.0	44.0	34.0	12.0	10.0	0.0	90.0	10.0	NA	NA	NA	100.0	0.0	96.0	4.0	90.0	8.0	2.0	96.0	4.0	0.0
HCPs: Trastuzumab (Vial)	17.3	69.2	11.5	1.9	40.4	51.9	7.7	7.7	55.8	40.4	3.8	67.3	13.5	5.8	13.5	1.9	59.6	38.5	NA	NA	NA	NA	NA	NA	NA	NA	1.9	46.2	51.9	7.7	92.3	100.0	15.4	84.6	44.2	23.1	23.1	7.7	1.9	82.7	17.3	5.8	38.5	55.8	94.2	5.8	96.2	3.8	100.0	0.0	0.0	94.2	0.0	5.8

"Participants were asked the following 5 questions: (1) Following the first injection given by the physician/nurse and training on how to use the SID, I felt comfortable injecting the study drug by myself; (2) The SID was convenient and easy to use; (3) I am confident giving myself an injection in the thigh with the SID; (4) Taking all things into account, I find self-administration using the SID satisfactory; (5) If given the opportunity, I would choose to continue self-injecting the study drug using the SID at home. Response to each question was recorded as either of the following options: Unknown, Strongly Disagree, Disagree, Unsure, Agree, Strongly Agree. Percentage of participants who provided responses to above questions was reported. Data for this outcome measure were analyzed and reported only for Trastuzumab (SID) arm." (NCT01940497)
Timeframe: After at least 14 cycles (1 cycle = 21 days; maximum up to 1 year)

Number of Participants With Serious and Non-Serious Adverse Events

Intervention	Percentage of Participants (Number)
	Comfortable: Unknown	Comfortable: Strongly Disagree	Comfortable: Disagree	Comfortable: Unsure	Comfortable: Agree	Comfortable: Strongly Agree	Convenient: Unknown	Convenient: Strongly Disagree	Convenient: Disagree	Convenient: Unsure	Convenient: Agree	Convenient: Strongly Agree	Confident: Unknown	Confident: Strongly Disagree	Confident: Disagree	Confident: Unsure	Confident: Agree	Confident: Strongly Agree	Satisfactory: Unknown	Satisfactory: Strongly Disagree	Satisfactory: Disagree	Satisfactory: Unsure	Satisfactory: Agree	Satisfactory: Strongly Agree	Would continue: Unknown	Would continue: Strongly Disagree	Would continue: Disagree	Would continue: Unsure	Would continue: Agree	Would continue: Strongly Agree
Trastuzumab (SID)	0.0	0.0	0.0	6.7	40	53.3	0.0	0.0	0.0	6.7	33.3	60	0.0	0.0	0.0	6.7	40.0	53.3	0.0	0.0	0.0	6.7	33.3	60	0.0	0.0	13.3	6.7	20	60

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01264081)
Timeframe: Date treatment consent signed to date off study, approximately, 3 years

Count of Participants With a Partial Response (PR) and Complete Response (CR) to Lapatinib Who Have Metastatic Melanoma Harboring ERBB4 Mutations.

Intervention	Participants (Count of Participants)
Lapatinib	3

The count of participants with a partial response and complete response is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Partial response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progressions. (NCT01264081)
Timeframe: 3 years

CNS Clinical Benefit Response

Intervention	Participants (Count of Participants)
	Partial Response	Complete Response	Stable Disease	Progressive Disease
Lapatinib	0	0	2	0

The number of patients with Complete Response, Partial Response or Stable Disease extending beyond 6 months (CR+PR+SD ≥ 6 months), determined by RECIST v1.1. CR=disappearance of all target and non-target lesions; PR=at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter AND an absolute decrease of at least 5mm in at least one target lesion; SD=Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of the longest diameter since the treatment started. (NCT01934894)
Timeframe: every 6 weeks thru cycle 8, and every 3 cycles thereafter until treatment discontinuation, projected 1 year

CNS Objective Response

Intervention	Participants (Count of Participants)
Dose Level 1 (20 mg/m^2 Cabazitaxel + Lapatinib)	2
Dose Level 2 (25 mg/m^2 Cabazitaxel + Lapatinib)	0

The number of patients with Complete and Partial Response (CR+PR) of CNS lesions assessed per modified RECIST Criteria for Evaluation of Intracranial Disease. CR=disappearance of all target and non-target lesions; PR=at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter AND an absolute decrease of at least 5mm in at least one target lesion. (NCT01934894)
Timeframe: every 6 weeks thru cycle 8, then every 9 weeks until treatment discontinuation, projected 1 year

Extra-Cranial Objective Response

Intervention	Participants (Count of Participants)
Dose Level 1 (20 mg/m^2 Cabazitaxel + Lapatinib)	0
Dose Level 2 (25 mg/m^2 Cabazitaxel + Lapatinib)	0

The number of participants having Complete and Partial Responses (CR+PR) of extra-cranial lesions assessed per RECIST v1.1 Criteria. CR=disappearance of all target and non-target lesions; PR=at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter AND an absolute decrease of at least 5mm in at least one target lesion. (NCT01934894)
Timeframe: every 6 weeks for 8 cycles, then every 9 weeks until treatment discontinuation, up to 1 year

Maximum Tolerated Dose of Cabazitaxel With Lapatinib

Intervention	Participants (Count of Participants)
Dose Level 1 (20 mg/m^2 Cabazitaxel + Lapatinib)	0
Dose Level 2 (25 mg/m^2 Cabazitaxel + Lapatinib)	0

The maximum tolerated dose (MTD) of cabazitaxel and lapatinib will be determined as the highest dose at which ≤1 of 6 patients experiences a dose-limiting toxicity (DLT) assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0. A listing of DLTs are reported in the subsequent Primary Outcome Measure. (NCT01934894)
Timeframe: weekly for 3 weeks

Number of Participants Who Experience Dose-Limiting Toxicities (DLTs) as a Measure of Safety

Intervention	mg/m^2 of cabazitaxel + lapatinib (Number)
Cabazitaxel and Lapatinib	NA

During the safety lead-in, a standard 3+3 dose escalation design is used to determine the maximum tolerated dose (MTD) of cabazitaxel with lapatinib. The MTD would be determined by the highest dose at which ≤1 of 6 patients experiences a dose-limiting toxicity (DLT) during 1 cycle (21 days) of therapy. If 2 of 6 patients within a dose level experiences a DLT, that dose level would be defined as exceeding the MTD and the previous dose level would be evaluated. DLTs are assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0. (NCT01934894)
Timeframe: weekly for 3 weeks

Article	Year
Fluoropyrimidine-Associated Cardiotoxicity. Cardiology clinics, 2019, Volume: 37, Issue:4 Topics: Antimetabolites, Antineoplastic; Cardiotoxicity; Fluorouracil; Global Health; Heart Diseases; Humans	2019
[Management of cardiovascular complications secondary to medical treatment of cancer]. Ugeskrift for laeger, 2018, Feb-12, Volume: 180, Issue:7 Topics: Anthracyclines; Antineoplastic Agents; Biomarkers; Cardiotoxicity; Echocardiography; Electrocardiogr	2018
Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer treatment reviews, 2013, Volume: 39, Issue:8 Topics: Capecitabine; Deoxycytidine; Fluorouracil; Heart Diseases; Humans; Prospective Studies; Retrospectiv	2013
Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:10 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxy	2013
[Adverse cardiac effects associated with anticancer drugs]. Duodecim; laaketieteellinen aikakauskirja, 2015, Volume: 131, Issue:5 Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug-Related Side Effects	2015
Fluoropyrimidine-associated cardiotoxicity: revisited. Expert opinion on drug safety, 2009, Volume: 8, Issue:2 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blo	2009
The spectrum of 5-fluorouracil cardiotoxicity. Anti-cancer drugs, 2009, Volume: 20, Issue:1 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arr	2009
5-fluorouracil induced cardiotoxicity: review of the literature. Cardiology journal, 2012, Volume: 19, Issue:5 Topics: Animals; Antimetabolites, Antineoplastic; Coronary Vessels; Drug Monitoring; Fluorouracil; Heart Dis	2012
Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. Clinical colorectal cancer, 2013, Volume: 12, Issue:1 Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cardiovascular Agents; Colorectal Neoplasms;	2013
[Cardiotoxicity of 5-fluorouracil]. Bulletin du cancer, 2004, Volume: 91 Suppl 3 Topics: Antimetabolites, Antineoplastic; Capecitabine; Coronary Thrombosis; Coronary Vessels; Deoxycytidine;	2004
Cardiotoxicity of 5-fluorouracil. Cardiovascular & hematological agents in medicinal chemistry, 2006, Volume: 4, Issue:1 Topics: Animals; Antimetabolites, Antineoplastic; Coronary Vasospasm; Endothelium, Vascular; Fluorouracil; H	2006
Cardiac toxicity: old and new issues in anti-cancer drugs. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008, Volume: 10, Issue:1 Topics: Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Agents; Aromatase Inhibitors; Capecitabine;	2008
Cardiotoxicity and cardioprotection during chemotherapy. Current opinion in oncology, 1995, Volume: 7, Issue:4 Topics: Adult; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Child; Clinical Trials as Topic	1995
Cardiotoxicity of chemotherapy. Current opinion in oncology, 1994, Volume: 6, Issue:4 Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi	1994
The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer, 1993, Jan-15, Volume: 71, Issue:2 Topics: Female; Fluorouracil; Heart Diseases; Humans; Middle Aged; Pyrimidines; Syndrome	1993
Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs, 1999, Volume: 57, Issue:4 Topics: Antimetabolites, Antineoplastic; Fluorouracil; Growth Inhibitors; Heart Diseases; Humans	1999
Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. American journal of clinical oncology, 1999, Volume: 22, Issue:5 Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma; Fluorouracil; Heart Diseases; Humans; Male; Tongu	1999
Circulatory shock. Critical care clinics, 2001, Volume: 17, Issue:3 Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Anthracyclines; Antineoplastic Agents; Carcinoid Tu	2001
New combinations with Herceptin in metastatic breast cancer. Oncology, 2001, Volume: 61 Suppl 2 Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo	2001
[Acute cardiac toxicity of 5-fluorouracil: pharmacokinetic correlation]. Bulletin du cancer, 1991, Volume: 78, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Heart Diseases; Humans; Inf	1991
5-Fluorouracil cardiotoxicity: a critical review. Annals of oncology : official journal of the European Society for Medical Oncology, 1990, Volume: 1, Issue:6 Topics: Animals; Fluorouracil; Heart Diseases; Humans; Incidence	1990
[Cardiotoxicity of continuous intravenous infusion of 5-fluorouracil: clinical study, prevention and physiopathology. Apropos of 13 cases]. Bulletin du cancer, 1990, Volume: 77, Issue:5 Topics: Adult; Aged; Angina Pectoris; Dose-Response Relationship, Drug; Electrocardiography; Female; Fluorou	1990
[Cardiotoxicity of 5-fluorouracil: coronary spasm? Apropos of 2 cases with normal coronarography]. Annales de medecine interne, 1989, Volume: 140, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Coronary Vasospasm; Electrocardiography; Female; Fluorouracil; Heart	1989
[Cardiotoxicity induced by 5-fluorouracil. Review of the literature]. Revista clinica espanola, 1989, Volume: 184, Issue:5 Topics: Adult; Aged; Female; Fluorouracil; Heart Diseases; Humans; Male; Middle Aged	1989
[Cardiac toxicity of 5-fluorouracil. Review of the literature, 5 new cases]. Presse medicale (Paris, France : 1983), 1988, Oct-01, Volume: 17, Issue:33 Topics: Arrhythmias, Cardiac; Female; Fluorouracil; Heart Diseases; Humans; Male; Middle Aged; Neoplasms; Ri	1988

Article	Year
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. European journal of cancer (Oxford, England : 1990), 2018, Volume: 105 Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols	2018
Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jan-15, Volume: 21, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc	2003
Long-term efficacy and toxicity of the FEC100 regimen. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis	2004
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:8 Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, A	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England journal of medicine, 2006, Dec-28, Volume: 355, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap	2006
A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:3 Topics: Administration, Oral; Adult; Aged; Alopecia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz	2008
A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study. American journal of clinical oncology, 1984, Volume: 7, Issue:3 Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials	1984
The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients. Cancer chemotherapy and pharmacology, 1994, Volume: 35, Issue:1 Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chroma	1994
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Feb-01, Volume: 19, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan	2001
A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus. Acta oncologica (Stockholm, Sweden), 2001, Volume: 40, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy,	2001
Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation. The Canadian journal of oncology, 1996, Volume: 6, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cost-Benefi	1996
Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer. Oncology, 1986, Volume: 43, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin;	1986

Article	Year
An unusual case of acute myopericarditis after the first dose of capecitabine: Need for new cardioprotective strategies and risk stratification. International journal of clinical pharmacology and therapeutics, 2021, Volume: 59, Issue:12 Topics: Capecitabine; Cardiotoxicity; Female; Fluorouracil; Heart Diseases; Humans; Middle Aged; Risk Assess	2021
Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy. Cardiovascular toxicology, 2022, Volume: 22, Issue:2 Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Decision	2022
Cardioprotective effects of bosentan in 5-fluorouracil-induced cardiotoxicity. Toxicology, 2022, 01-15, Volume: 465 Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antioxidants; Apoptosis; Bosenta	2022
Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin. Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neopl	2023
Use of spectral tracking technique to evaluate the changes in left ventricular function in patients undergoing chemotherapy for colorectal cancer. The international journal of cardiovascular imaging, 2021, Volume: 37, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomechanical Phenomena; Cardiotoxicity; Colo	2021
Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study. Cancer communications (London, England), 2018, 05-11, Volume: 38, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capeci	2018
Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal. Clinical colorectal cancer, 2019, Volume: 18, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotoxicity; Clinical Trials, Phase	2019
Temporal changes in standard and tissue Doppler imaging echocardiographic parameters after anthracycline chemotherapy in women with breast cancer. The American journal of cardiology, 2013, Oct-01, Volume: 112, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel	2013
Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma. The International journal of biological markers, 2013, Dec-17, Volume: 28, Issue:4 Topics: Adult; Aged; Angiotensinogen; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast	2013
Comparative cardiac toxicity in two treatment schedules of 5-FU/LV for colorectal carcinoma. Pakistan journal of pharmaceutical sciences, 2013, Volume: 26, Issue:5 Topics: Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Pressure; Carcino	2013
Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman. Diagnostic pathology, 2013, Sep-16, Volume: 8 Topics: Acute Disease; Adenocarcinoma; Adult; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protoco	2013
Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci	2014
A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives. Toxicology letters, 2014, Jun-16, Volume: 227, Issue:3 Topics: Animals; Antimetabolites; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Fluorour	2014
[Risk factors for cardiotoxicity during fluorouracil and cisplatin combination chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Heart Disease	2014
Tranexamic acid and fibrinogen restore clotting in vitro and in vivo in cardiac thrombus associated hyperfibrinolysis with overt bleedings. Thrombosis and haemostasis, 2014, Volume: 112, Issue:5 Topics: Adenocarcinoma; Aged; Anemia; Antifibrinolytic Agents; Antineoplastic Combined Chemotherapy Protocol	2014
Right atrial thrombus from inferior vena cava after acute cardiotoxicity of 5-fluorouracil. Cardiology journal, 2008, Volume: 15, Issue:3 Topics: Antimetabolites, Antineoplastic; Echocardiography; Female; Fluorouracil; Heart Atria; Heart Diseases	2008
Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2009, Volume: 90, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distributi	2009
[High risk of cardiac dysfunction after treatment of secondary acute myeloid leukemia following chemotherapy and radiotherapy for breast cancer]. Bulletin du cancer, 2010, Volume: 97, Issue:2 Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy	2010
[Cardiotoxicity induced by 5-fluorouracil or capecitabine]. Ugeskrift for laeger, 2010, Jan-04, Volume: 172, Issue:1 Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; He	2010
Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer. American journal of clinical oncology, 2012, Volume: 35, Issue:3 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms;	2012
Occurrence of subacute cutaneous lupus erythematosus after treatment with systemic fluorouracil. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-10, Volume: 29, Issue:20 Topics: Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Heart Diseases; Humans; Lupus Ery	2011
A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center. JPMA. The Journal of the Pakistan Medical Association, 2012, Volume: 62, Issue:5 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bradycardia;	2012
5-Flourouracil cardiotoxicity - an elusive cardiopathy: case report. The Gulf journal of oncology, 2012, Issue:12 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Fluorouracil; Heart Diseases; Humans; Male; Middle Age	2012
Cardiac toxicity associated with capecitabine therapy. Acta oncologica (Stockholm, Sweden), 2003, Volume: 42, Issue:4 Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diagnosis, Differential; Electrocardio	2003
[DIGESTIVE INTOLERANCE TO DIGITALIN, CYTOSTATIC DRUGS AND VARIOUS THERAPEUTIC DRUGS. THEIR TREATMENT WITH METHOCLOPRAMIDE]. La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1964, Oct-14, Volume: 40 Topics: Antiemetics; Antitubercular Agents; Cobalt Isotopes; Cyclophosphamide; Cytostatic Agents; Digitalis	1964
A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab. Expert opinion on biological therapy, 2005, Volume: 5, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop	2005
Cardiotoxicity resembling myocardial infarction that occurs during chemotherapy with 5-fluorouracil. Saudi medical journal, 2005, Volume: 26, Issue:11 Topics: Adenocarcinoma; Adult; Chest Pain; Colonic Neoplasms; Diagnosis, Differential; Electrocardiography;	2005
Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34 Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti	2005
Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Atherosclerosis; Capecitabine;	2006
Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. Bulletin du cancer, 2006, Mar-01, Volume: 93, Issue:3 Topics: Adult; Aged; Angina Pectoris; Antimetabolites, Antineoplastic; Cardiac Output, Low; Chest Pain; Fema	2006
Left ventricular thrombus in a patient with esophageal carcinoma. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2007, Volume: 7, Issue:1 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Diagnosis, Differential; Esophageal Neoplasms; Fluo	2007
Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:1 Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorec	2008
Capecitabine-related cardiotoxicity: recognition and management. The journal of supportive oncology, 2008, Volume: 6, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deo	2008
Bleomycin infusion followed by cyclophosphamide, methotrexate, and 5-fluorouracil in advanced squamous carcinoma of the head and neck. Cancer, 1984, Feb-15, Volume: 53, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cy	1984
Effect of coadministration of uracil on the toxicity of tegafur. Journal of pharmaceutical sciences, 1984, Volume: 73, Issue:2 Topics: Animals; beta-Alanine; Cats; Dogs; Female; Fluorouracil; Heart Diseases; Lethal Dose 50; Male; Mice;	1984
[Does 5-fluorouracil cardiotoxicity exist? Presentation of 2 cases with acute manifestations and clinico-instrumental study of 12 cases in chronic treatment with 5-fluorouracil]. Minerva cardioangiologica, 1984, Volume: 32, Issue:9 Topics: Adult; Aged; Coronary Disease; Electrocardiography; Female; Fluorouracil; Heart Diseases; Humans; Ma	1984
Drug-induced cardionecrosis. Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement, 1984, Volume: 7 Topics: Anesthetics; Antibiotics, Antineoplastic; Antidepressive Agents; Antineoplastic Agents; Calcium; Cyc	1984
Cardiotoxicity of 5-fluoro-uracil. A case report. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1982, Apr-24, Volume: 61, Issue:17 Topics: Electrocardiography; Female; Fluorouracil; Heart; Heart Diseases; Humans; Middle Aged	1982
[Cardiotoxicity of 5-fluorouracil: a question of formulation]. Bulletin du cancer, 1994, Volume: 81, Issue:12 Topics: Animals; Chemistry, Pharmaceutical; Drug Stability; Fluorouracil; Heart Diseases; Rabbits; Risk Fact	1994
5-Fluorouracil cardiotoxicity with left ventricular dysfunction under different dosing regimens. The American journal of cardiology, 1995, Jan-15, Volume: 75, Issue:2 Topics: Adult; Dose-Response Relationship, Drug; Female; Fluorouracil; Heart Diseases; Humans; Male; Middle	1995
Changes of blood viscosity in patients treated with 5-fluorouracil--a link to cardiotoxicity? Acta oncologica (Stockholm, Sweden), 1995, Volume: 34, Issue:1 Topics: Adult; Aged; Blood Viscosity; Carcinoma, Squamous Cell; Fibrinogen; Fluorouracil; Head and Neck Neop	1995
The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy. Cancer, 1994, Apr-01, Volume: 73, Issue:7 Topics: Adenocarcinoma; Angina Pectoris; Electrocardiography; Female; Fluorouracil; Heart; Heart Diseases; H	1994
[Does leucovorin increase the cardiotoxicity of 5-fluorouracil?]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1994, Volume: 170, Issue:3 Topics: Fluorouracil; Heart Diseases; Humans; Leucovorin	1994
Clinical cardiotoxicity of 5-fluorouracil. Journal of clinical pharmacology, 1993, Volume: 33, Issue:11 Topics: Aged; Arrhythmias, Cardiac; Coronary Vasospasm; Electrocardiography; Female; Fluorouracil; Heart Arr	1993
Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer, 1993, Oct-01, Volume: 72, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Coronary Disease;	1993
The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy. Cancer, 1993, Oct-01, Volume: 72, Issue:7 Topics: Angina Pectoris; Fluorouracil; Heart Diseases; Humans; Myocardial Infarction	1993
5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:2 Topics: Adolescent; Antimetabolites, Antineoplastic; Female; Fluorouracil; Heart; Heart Diseases; Humans	1996
[Chemotherapy and cardiotoxicity]. Annales de cardiologie et d'angeiologie, 1995, Volume: 44, Issue:8 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Chronic Disease; Drug Synergism; Drug Therapy, C	1995
Adjuvant chemotherapy with doxorubicin-containing regimen for 326 stage II breast cancers: 15-year results. American journal of clinical oncology, 1997, Volume: 20, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br	1997
Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:13 Topics: Antimetabolites, Antineoplastic; Cell Culture Techniques; Dihydrouracil Dehydrogenase (NADP); Female	1997
Endothelin-1 and 5-fluorouracil-induced cardiotoxicity. Neoplasma, 1998, Volume: 45, Issue:2 Topics: Aged; Antimetabolites, Antineoplastic; Coronary Vasospasm; Endothelin-1; Female; Fluorouracil; Heart	1998
Acute reversible cardiomyopathy and thromboembolism after cisplatin and 5-fluorouracil chemotherapy--a case report. Angiology, 2000, Volume: 51, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cardiomyopathies; Cisplati	2000
[Cardiotoxicity of 5-fluorouracil: ischemia or myocardial toxicity?]. Revista clinica espanola, 2001, Volume: 201, Issue:2 Topics: Adult; Antimetabolites, Antineoplastic; Electrocardiography; Fluorouracil; Heart; Heart Diseases; Hu	2001
5-fluorouracil-induced cardiotoxicity mimicking myocardial infarction: a case report. BMC cardiovascular disorders, 2001, Volume: 1 Topics: Aged; Antimetabolites, Antineoplastic; Chest Pain; Coronary Angiography; Coronary Vasospasm; Diagnos	2001
Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:3 Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Hear	2002
Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques. Heart (British Cardiac Society), 2002, Volume: 88, Issue:1 Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms	2002
Fluorouracil cardiotoxicity. British medical journal, 1978, Apr-29, Volume: 1, Issue:6120 Topics: Fluorouracil; Heart Diseases; Humans	1978
Fluorouracil cardiotoxicity. British medical journal, 1978, May-27, Volume: 1, Issue:6124 Topics: Fluorouracil; Heart Diseases; Humans; Pain	1978
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:11 Topics: Adult; Aged; Echocardiography; Electrocardiography; Female; Fluoroacetates; Fluorouracil; Heart Dise	1992
Very high endothelin plasma levels in patients with 5-FU cardiotoxicity. Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3, Issue:1 Topics: Adult; Aged; Endothelins; Female; Fluorouracil; Heart Diseases; Humans; Male; Middle Aged; Neoplasms	1992
[Cardiac toxicity of fluoro-uracil. Typical and atypical aspects. Apropos of 8 cases]. Annales de cardiologie et d'angeiologie, 1992, Volume: 41, Issue:4 Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiomyopathies; Coronary Disease; Fluorouracil; Heart Diseases;	1992
[Cardiotoxicity of fluorouracil: a real but unexplained phenomenon]. Presse medicale (Paris, France : 1983), 1991, Nov-09, Volume: 20, Issue:36 Topics: Fluorouracil; Heart Diseases; Humans; Male; Middle Aged	1991
[Cardiac toxicity of 5-fluorouracil. Two cases]. Presse medicale (Paris, France : 1983), 1991, Mar-16, Volume: 20, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cispl	1991
[Possible cardiotoxicity induced by orally administered fluoropyrimidines]. Anales de medicina interna (Madrid, Spain : 1984), 1990, Volume: 7, Issue:10 Topics: Administration, Oral; Aged; Fluorouracil; Heart Diseases; Humans; Male; Middle Aged; Tegafur	1990
[Evaluation of acute cardiotoxicity from the combination cyclophosphamide-mitoxantrone-5-fluorouracil (CMF) with Holter ECG]. Minerva cardioangiologica, 1990, Volume: 38, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Electrocardiography, Ambulatory; F	1990
Pirarubicin in combination chemotherapy for metastatic breast cancer. American journal of clinical oncology, 1990, Volume: 13 Suppl 1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox	1990
High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer--a phase II study in elderly patients or patients with cardiac risk. Investigational new drugs, 1990, Volume: 8, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Female; Fluorourac	1990
[5-Fluorouracil (5-FU) cardiotoxicity. Evaluation by dynamic ECG]. Recenti progressi in medicina, 1986, Volume: 77, Issue:1 Topics: Adult; Cardiac Complexes, Premature; Electrocardiography; Fluorouracil; Heart Diseases; Heart Rate;	1986
The clinical syndrome of 5-fluorouracil cardiotoxicity. Investigational new drugs, 1989, Volume: 7, Issue:1 Topics: Adult; Aged; Coronary Disease; Death, Sudden; Electrocardiography; Female; Fluorouracil; Heart Disea	1989
[Cardiotoxicity of 5-fluorouracil. Characteristics, mechanism, practical management]. Presse medicale (Paris, France : 1983), 1986, Oct-18, Volume: 15, Issue:36 Topics: Coronary Disease; Coronary Vasospasm; Female; Fluorouracil; Heart Diseases; Humans; Male; Middle Age	1986
Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. The American journal of medicine, 1985, Volume: 78, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo	1985
Early and delayed clinical cardiotoxicity of doxorubicin. Cancer, 1985, Jun-15, Volume: 55, Issue:12 Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cyclo	1985

fluorouracil and Cardiac Diseases